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INTRODUCTION: 
The solubility/dissolution behavior of a drug is key 
determinant to its oral bioavailability, the latest 
frequency being the rate-limiting step of absorption of 
drugs from the gastrointestinal tract. As a result, more 
than 40% of new candidates entering drug development 
pipeline fail because of non optimal biopharmaceutical 
properties 
1
. Several researchers have shown that the 
liquisolid technique is the most promising method for 
promoting dissolution rate of poorly water soluble 
drugs 
2, 3
. The liquisolid technology is described by 
Spireas as liquid may be transformed into a free-
flowing, readily compressible, and apparently dry 
powder by simple physical blending with selected 
excipients named the carrier and coating material 
(Figure 1).  
A more recent technique, entitled powdered solution 
technology, has been applied to prepare water-
insoluble drugs into rapid-release solid dosage forms. 
Powdered solutions are designed to contain liquid 
medications in powdered form. The concept of 
powdered solutions enables one to convert a liquid 
drug or poorly water-soluble solid drug dissolved in a 
suitable non-volatile solvent into a dry, non-adherent, 
free-flowing and readily compressible powder by its 
simple admixture with selected carrier and coating 
materials. This method does not involve drying or 
evaporation. It is well established that better 
bioavailability of a relatively water-insoluble drug is 
achieved when the drug is in solution form. Absorption 
of a liquid by a powder material occurs when the 
absorbate molecules diffuse inside the absorbent and 
are eventually captured and held by the powder 
particles within their bulk. In some cases, the liquid is 
not truly absorbed, and instead of being dispersed 
throughout the interior of the solid, the liquid 
molecules only cling to its available surface i.e., 
internal and external. This process is known as 
adsorption. 
4, 5
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ABSTRACT:  
The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble piroxicam by 
utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required 
quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different 
formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)  and Avicel P
H
 102, 
binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug 
release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the 
amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of 
carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform 
infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The 
FTIR spectra showed disappearance of the characteristic absorption band of piroxicam (3338.78 cm-1) in liquisolid formulations 
which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug 
dissolution enhancement. A 2
3 
factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and 
Avicel P
H
 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification 
limits with respect to weight variation, hardness, friability and content uniformity.  The In-vitro drug release from these liquid soild 
compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical 
mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active 
pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical 
ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of oxicam derivative, which in turn promotes 
in enhancing bioavailability. 
Keywords: Piroxicam, Factorial design, Solubility, Dissolution rate, Avicel P
H
 102 
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Figure 1: Schematic representation of liquisolid systems. 
 
Piroxicam is an oxicam derivative with potent non-
steroidal anti-inflammatory activity (NSAID). It is used 
in various acute and chronic musculoskeletal and joint 
disorders such as ankylosing spondylitis, osteoarthritis 
and rheumatoid arthritis and in acute gout, 
dysmenorrhoea and sometimes for pain associated with 
inflammation 9. For poorly soluble, highly permeable 
(class II) drugs (like piroxicam), the rate of oral 
absorption is often controlled by the dissolution rate in 
the gastrointestinal (GI) tract. 
6
. 
Compressible liquid retention potential is the 
compression force applied to produce tablets with 
acceptable strength without squeezing out any liquid 
during compression. Excipient ratio (R) is defined as 
carrier to coating ratio quoted as given by equation (1) 
R= Q/q (1) 
Where, Q = Carrier material and q = Coating material. 
Liquid load factor (L
f
) is defined as the weight of liquid 
medicament (W) to the weight of carrier (w). The 
equation is given below (2)  
L
f
= W/Q (2) 
The Ø value is for calculating excipients quantities as 
shown in the equation (3).  
L
f =
 Ø+Ø (1/R) (3) 
Where, Ø and Ø are values of carrier and coating 
material. 
7
 
MATERIALS AND METHODS: 
Piroxicam is a gift sample Sun Pharmaceuticals 
Haridwar, Neusilin (Magnesium aluminometasilicate) 
were obtained as gift sample from Fuji Chemical 
Industry Co. Ltd., Japan. 
Aerosil 200, PVP K-30, Avicel P
H
 102, Magnesium 
stearate, Lactose, Propylene glycol (PG), Glycerine, 
Tween 80, PEG 300 are procured from S. D. Fine 
Chem Limited, Mumbai and used in the study. PEG 
400 obtained from fischer scinetific pvt. Ltd. 
Solubility studies: 
Solubility studies of oxicam derivative were carried out 
in SGF, SIF, propylene glycol and PEG 400. Saturated 
solutions were fabricated by adding surplus API to the 
vehicles and shaking on the shaker for 48h at 25±0.5°C 
under unvarying vibration. After this period the 
solutions were filtered, diluted and analysed by 
Uvspectrophotometer. Three determinations were 
carried out for each sample to reckon the solubility of 
piroxicam.
8
 
Piroxicam estimation by UV: 
Piroxicam estimation was made in 0.1N hydrochloric 
acid (pH 1.2) solution at λ
max 
of 333 nm by UV 
spectrophotometry. The calibration curve was obeyed 
Beer Lambert’s law in the concentration range of 0-40 
μg/ml (R
2
= 0.997) 
9
.  
Characterization of piroxicam: 
The efavirenz purity was characterized by melting 
point, FT-IR studies, DSC studies and XRD studies. 
The micrometric properties of piroxicam were 
determined by the angle of repose, bulk density, tapped 
density, compressibility index, and Hausner’s ratio.  
Drug-excipient compatibility studies: 
The excipients used in the formulation were selected 
from drug-excipients compatibility studies using 
spectral interference and Fourier Transform Infrared 
(FTIR) Spectroscopy analysis. 
Determination of the flowable liquid retention 
potential: 
In constant weight of coating material, escalating 
amount of solvent was incorporated and on each 
addition, the angle of slide was determined. The 
Flowable liquid retention potential (Ø-value) of each 
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liquid/powder admixture was calculated using the 
following equation (4).  
Ø− value = weight of liquid weight of solid .... (4) 
The Ø-values were plotted against the corresponding 
angle of the slide to identify optimal flow properties. 
The angle of slide value of 32
o 
corresponding to the 
liquid/powder admixture is represented as the ideal 
Flowable liquid-retention potential 
10
. 
Formulation development: 
The liquisolid compacts of efavirenz were developed 
by using 2
3
factorial design, i.e., 3 variables and 2 
levels. The variables include the concentration of drug 
in the liquid vehicle (% w/w), concentration of binding 
agent (PVP K-30) in the formulation (%w/w) and 
concentration of super disintegrant (cross caramellose 
sodium) in the formulation (%w/w). The factorial 
design was applied at lower and higher levels using 
two different carries (Neusilin and Avicel P
H
 102) and 
developed eight formulations for each carrier. The 
absolute levels of variables used in the study are given 
in the table 1 and the plan of experiments with coded 
levels of variables is given in the table 2. 
 
Table 1: Absolute values of levels of variables employed in factorial design 
S.N. Variables Levels 
Absolute Coded         -1                +1 
1 Concentration of drug in the liquid vehicle (% w/w)   X
1
 50 75 
2 Concentration of PVP-K30 in the formulation (% w/w)      X2 2.5 5.5 
3 Concentration of super disintegrant in the formulation (% w/w) X3 2 5.5 
 
Table 2: Plan of experiments with coded values of variables of efavirenz liquisolid compacts formulation using 
2
3
design 
9
 
S.No Order of run Drug concentration in 
the liquid vehicle (% 
w/w)  
 
Concentration of PVP-
K30 in the formulation 
(% w/w) 
Concentration of cross 
caramellose sodium in the 
formulation (% w/w) 
01. LSC1 -1 -1 -1 
02. LSC2 +1 -1 -1 
03. LSC3 -1 +1 -1 
04. LSC4 +1 +1 -1 
05. LSC5 -1 -1 +1 
06. LSC6 +1 -1 +1 
07. LSC7 -1 +1 +1 
08. LSC8 +1 +1 +1 
 
 
Characterization of liquisolid compacts: 
Flow property: 
Flow property of liquisolid admixture was accessed by 
measuring the angle of repose, Carr’s index and 
Hausner’s ratio. Each study was carried out in 
triplicate. The angle of repose was calculated by a 
fixed height cone method. Carr’s index & Hausner’s 
ratio were determined using bulk density apparatus as 
reported in the literature 
11
. 
Weight variation: 
 Weight variation was calculated as per method 
described in USP. Twenty tablets were selected at 
random and their average weight was determined using 
an electronic balance. The tablets were weighed 
individually and compared with average weight. The 
requirements are met if the weights of not more than 2 
of tablets differ by more than the percentage listed in 
the table 3 and no tablets differ in weight by more than 
double that percentage 
12
. 
 
Table 3: Acceptance criteria for weight variation 
S.No Average weight of tablet 
(mg)  
 
%±deviation 
allowed 
01. 130 or less 10 
02. More than 130 & less than 324 7.5 
03. 324 and above 5 
 
Tablet thickness: 
 Thickness and diameter of formulation trials were 
measured using a digital hardness tester. 10 tablets of 
each trial formulation were taken and measured 
individually at frequent intervals 
13
.  
Hardness: 
The hardness of the liquisolid tablets was evaluated 
using a Monsanto hardness tester. The tablet to be 
tested was placed between the spindle and the anvil. 
The desired pressure needed to hold the tablet in 
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position was applied by moving the screw knob in a 
clockwise direction. The scale was moved so that the 
indicator was fixed at zero. The pressure was applied 
until tablet breaks. The reading was noted, indicating 
the pressure that was needed to break the tablet. The 
mean hardness of each batch was determined and 
expressed in kg/cm
2 
14
.  
Disintegration time: 
Disintegration test was carried out using USP tablet 
disintegration test apparatus using of 0.1N 
hydrochloric acid at room temperature (37±2 ⁰C). 
Disintegration apparatus with a basket rack assembly 
containing six open-ended tubes and 10-mesh screen 
on the bottom was used. A tablet was placed in each 
tube of the basket and the time for complete 
disintegration of the six tablets was recorded 
15
. 
Content uniformity: 
Ten tablets from each formulation were powdered. The 
powdered sample equivalent to 5 mg of active 
pharmaceutical ingredient was transferred to a 100 ml 
volumetric flask containing 5 ml of 0.1N hydrochloric 
acid solution. The contents were shaken up to 30 min 
and made up to mark with HCl. The solution was 
further diluted with 0.1N Hydrochloric acid solution if 
required. The drug content was determined by 
measuring the absorbance at 247 nm 
16
.  
In-vitro drug releases study: 
In vitro drug release of the samples was carried out 
using USP-type II dissolution apparatus. The 
temperature of the medium was maintained at 37±0.5 
°C. The apparatus was allowed to run for 50 RPM. 
Aliquots of samples were withdrawn at various 
intervals. The samples were filtered through Whatman 
filter. Fresh dissolution medium (0.1N HCl solution) 
was replaced every time with the same quantity of the 
sample. Collected samples were analyzed at λ
max
 333 
nm. The percentage cumulative drug release was 
calculated 
17
. 
RESULT AND DISCUSSION: 
FT-IR spectrum of active pharmaceutical 
ingredient: 
The FT-IR was performed to detect any sign of 
interaction which would be reflected by a change in 
the position or disappearance of any characteristic 
stretching vibration of piroxicam. FTIR spectra of 
piroxicam show a band at 3338.78 cm-1 (Figure 2) 
which indicates that the drug is in the cubic 
polymorphic form. Other characteristic bands are 
attributed to the stretching of different group 
vibrations: 1629.85 cm-1 stretching of amide carbonyl, 
1529 cm- 
1
 stretching of the second amide band, 1435 
cm- 
1
 stretching of asymmetric methyl group, 1352 
cm- 
1
 stretching of symmetric methyl group, 1149 cm-
1
 
stretching of –SO2-N- group and 775 cm- 1 as 
stretching of ortho-disubstitued phenyl [23]. Pattern of 
conventional formulation show band at 3336.88 cm- 
1
 
which indicates that the piroxicam was remained in the 
cubic polymorphic form and no interaction with 
excipients occurred. 
18 
 
 
Figure 2:  FTIR spectra of active pharmaceutical ingredient piroxicam 
 
XRD of active pharmaceutical ingredient: 
The purity and crystallinity of efavirenz was identified using XRD studies. The XRD graph of piroxicam was 
recorded in the figure 3. The XRD studies confirm the crystalline nature of the drug.  
 
Figure 3: XRD graph of piroxicam 
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Drug–excipients compatibility studies:  
Spectral interference analysis:  
The absorbance of the solutions containing drug (10 
μg/ml) and for a drug with the excipients mixture in 0.1 
N HCl solutions were measured at 333 nm to find out 
the influence of excipients on drug substance table 4. 
The absorbances of the solutions (drug and additive) 
were nearly closer to the absorbance of the drug 
solution. Thus, the analysis exposed that drug has no 
interference with the excipients used in the 
formulation. 
Table 4: Data obtained in the spectral interference 
analysis 
S.No Sample Absorabnce 
01. Drug solution without additive  0.489 
02. Drug solution with Avicel P
H
 
102 
0.490 
03. Drug solution with PEG-400 0.492 
04. Drug solution with PVP K-30  0.487 
05. Drug solution with Aerosil 200  0.496 
06. Drug solution with Neusilin 0.509 
 
Saturation solubility study  
The solubility studies for piroxicam in different 
solvents showed a varied solubility as shown in the 
figure 4. The highest solubility of the drug was 
observed in PEG 400 among the various solvents used 
in the study. Hence, PEG 400 was selected as a non-
solvent in the formulation of liquisolid compacts of 
efavirenz. 
 
Figure 4: Solubility studies of piroxicam in different 
solvents 
Differential scanning calorimetry: 
DSC was performed in order to assess the thermotropic 
propertiesand thermal behavior of the drug (Piroxicam) 
and the liquisolidcompacts prepared. The DSC 
thermogram of the drug figure 5 indicating a sharp 
characteristic peak around its melting point. This 
shows that Piroxicam used was in pure crystalline state. 
 
Figure 5: DSC thermogram of piroxicam 
Characterization of tablets of liquisolid: 
Flow properties: Bulk density: 
It is the ratio of given mass of powder and its bulk 
volume determined by measuring the volume of known 
mass powder sample that has been passed through the 
screen into graduating cylinder. Bulk density was 
determined according to USP method I. The powder 
sample under test was screened through sieve no 18 
and an appropriate amount of pure drug and the 
formulation blend were accurately weighed and filled 
in a 100 mL graduated cylinder and the powder were 
leveled and the unsettled volume (V
o
) was noted. Bulk 
density (D
b
) was calculated in g/ml by the formula:  
    D
b 
= M/V
o
 
M= Mass of powder taken 
Vo= Unsettled apparent volume 
 
Flowable liquid retention potential (Φ–value)  
This test is performed at 3 different ratios of carrier and 
coating material (i.e., R at 20, 25, and 30).
 
Table 5: Flowable liquid load factor (Lf) for various R values 
R 1/R Flowable liquid load factor(L
f
)  
Neusilin Avicel P
H
 102 
20 0.06 0.859 0.696 
25 0.08 0.966 0.758 
30 0.09 0.995 0.852 
 
Tapped density  
After carrying out the procedure as given in the 
measurement of bulk density, the cylinder containing 
the sample was tapped using a mechanically tapped 
density tester (Electro lab). The cylinder was tapped 
until no change in volume and then tapped volume Vt 
was measured to the nearest graduated unit. The 
tapped density was calculated, in grams per mL, using 
the formula:  
D
t 
= M/V
t 
0 
10 
20 
30 
40 
50 
60 
70 
SGF (PH 1.2) Propylene 
Glycols 
SIF (PH6.8) PEG400 
Solubility 
(mg/ml) 
Non volatile solvents 
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Where, M = weight of sample powder 
Vt = final tapped volume 
Compressibility index (% Compressibility): 
Carr's compressibility index, i.e., % compressibility 
indicates the flow property and packing ability of the 
tablet. It is determined by measuring both the bulk and 
tapped density of a powder. When the % 
compressibility ranges from 5 to16, the materials have 
acceptable flow property and packing ability. 
Compressibility Index was calculated using following 
equation: 
CI (%) = (D
t
-D
b
)/D
t
] x 100 
Where, D
t
= Tapped density 
D 
b
= Bulk density 
Hausner's ratio: 
The Hausner's ratio indicates the flowability and 
packing ability of the tablet. When the Hauser's ratio is 
close to 1, materials have acceptable flow and packing 
ability. Hausner's ratio was calculated using the 
formula:  
Hausner's ratio = D
t
/D
b
 
Where, D
t
= Tapped density 
D 
b 
= Bulk density
 
Table 6: Correlation of compressibility index and Hausner’s ratio with flow properties 
Compressibility Index Flow character Hausner’s ratio 
1-10 Excellent 1.00–1.11 
11-16 Good 1.12–1.18 
16-20 Fair 1.19–1.25 
21-25 Passable 1.26–1.34 
26-31 Poor 1.35–1.45 
32-37 Very poor 1.46–1.59 
≥38 Very, very poor ≥ 1.60 
 
Weight variation test: 
Weight variation was calculated as per method 
described in USP. Twenty tablets were selected at 
random and their average weight was determined using 
an electronic balance. The tablets were weighed 
individually and compared with average weight. The 
requirements are met if the weights of not more than 2 
tablets differ by more than the percentage listed  and 
no tablets differ in weight by more than double that 
percentage. 
Thickness: 
Thickness and diameter of formulation trials were 
measured using a digital hardness tester. 10 tablets of 
each trial formulation were taken and considered 
individually at frequent intervals.  The thickness of 
formulations LSCN1 to LSCN8 was found to be in the 
range of 2.27 mm to 4.67 mm and the formulations 
LSCA1 to LSCA8 was found to be in the range of 3.57 
mm to 4.88 mm 
Content uniformity:  
Ten tablets from each formulation were powdered. The 
powdered sample equivalent to 100 mg of drug was 
transferred to a 100 ml volumetric flask containing 100 
ml of methanol. The contents were shaken up to 30 
min. The solution was further diluted with 1% SLS 
solution. The drug content was determined by 
measuring the absorbance at 333 nm.  
Drug content for formulations LSCN1 to LSCN8 was 
found to be in the range of 97.45-98.09%. In the case 
of LSCA1 to LSCA8 was found to be in the range of 
98.45-99.76%. 
Disintegration time: 
 Disintegration test, measured using USP tablet 
disintegration test apparatus using 900 ml of distilled 
water at room temperature (37±2 ⁰C). For a drug to be 
absorbed from a solid dosage form after oral 
administration, it must first be in solution, and the 
condition is breakup of the tablet, a process called 
disintegration. The disintegration test is a measure of 
the time required under a given set of conditions for a 
group of tablets to disintegrate into particles which 
will pass through a 10 mesh screen. Generally the test 
is useful as a quality assurance tool for dosage forms. 
The tablet disintegration time ranges from 125 to 235 
seconds for LSCN1 to LSCN8 formulations and 132 to 
222 seconds for LSCA1 to LSCA8. The disintegration 
time was found to within the tolerable range. It is 
clearly obvious that as the concentration of 
disintegrant augmented, the disintegration time 
declined. 
In-vitro dissolution studies: 
All the prepared liquisolid compacts of piroxicam 
using neusilin and Avicel P
H
 102 were subjected for 
in-vitro drug release studies. The dissolution studies 
were conducted simultaneously for the active 
pharmaceutical ingredient and for the physical mixture 
(tablet) in 0.1 N hydrochloric acid solution using 
Type-II apparatus. All the studies were conducted in 
triplicate at 50 rpm and at 37±0.5 °C. 
The release data obtained for the best formulations 
(LSCN8 and LSCA8) along with pure drug and 
physical mixture were tabulated as a ready reference in 
table 7 and the data was plotted in the figure 6.
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Table 7: In-vitro dissolution data obtained for LSCA8, pure drug and physical mixture 
S.No Percentage cumulative drug release 
LSCA8 Physical mixture Active pharmaceutical ingredient 
0 0 0 0 
5 52.81 9.11 3.54 
10 73.49 16.90 8.98 
15 79.99 23.31 13.78 
20 84.39 29.89 18.44 
25 91.23 35.52 21.90 
30 95.39 38.89 24.45 
35 98.56 42.20 29.90 
 
 
Figure 6: Comparative in-vitro dissolution profile of the 
optimized formulation LSCA8, pure drug and physical 
mixture 
CONCLUSION:  
Piroxicam being a poorly water soluble drug can be 
made to make available a better treatment if the drug is 
released effectively and this is attained by formulating 
the drug as liquisolid compacts. A 2
3
factorial design 
was employed and developed 8 different formulations 
for each of neusilin and Avicel P
H
 102 as carrier 
materials. The PEG 400 was chosen as the best non-
solvent based on the saturation solubility studies. The 
formulated liquisolid compacts were characterized for 
an assortment of physicochemical studies and in-vitro 
release studies, which indicated the formulations, 
shower better drug release in comparison to pure drug 
and physical mixture.  
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